Pfizer (PFE)
(Delayed Data from NYSE)
$29.16 USD
-0.18 (-0.61%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $29.15 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
PFE 29.16 -0.18(-0.61%)
Will PFE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
Other News for PFE
Trending stocks in another record week for Wall Street
How To Create A SWAN Portfolio For Financial Freedom
Pfizer announces FDA approval of Hympavzi to reduce bleeding episodes
SCHD's 3 Best Dividend Buys (And 5 You Should Avoid)
Roche gets FDA approval for Itovebi combo therapy for breast cancer